Premium
Transfusion‐transmitted virus is not present in factor IX concentrates commonly used to treat haemophilia B
Author(s) -
Oza V. M.,
Jabbar A. A.,
Hakobyan N.,
Kazarian T.,
Valentino L. A.
Publication year - 2004
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2004.01048.x
Subject(s) - medicine , haemophilia , factor ix , virology , clotting factor , haemophilia b , virus , haemophilia a , hepatitis c virus , pediatrics
Summary. Transfusion‐transmitted virus (TTV) is a potential cause of post‐transfusion hepatitis in patients with haemophilia. Plasma‐derived clotting factor concentrates currently undergo processes that are effective in removal and inactivation of viruses such as HIV, hepatitis B and C; however, their effectiveness with respect to TTV is unknown. To determine if TTV DNA is present in plasma‐derived concentrates of factor IX, we tested 14 lots of Mononine ® and compared the results with B ene F ix ®. Nucleic acid isolation, followed by a two‐round polymerase chain reaction (PCR) and agarose gel analysis indicated that all 17 lots were negative for TTV. Although TTV may be considered an emerging pathogen, no evidence of the virus was detected in the commercially available plasma‐derived concentrate of FIX most commonly used to treat haemophilia B.